Long-term hepatitis C treatment does not reduce liver damage in large US study
This article was originally published in Scrip
Executive Summary
Long-term therapy with peginterferon does not reduce the rate of disease progression in patients with chronic hepatitis C who have not had an initial response to initial treatment with peginterferon and ribavirin, according to the results of a trial called HALT-C. The trial was published recently in the NEJM and was funded by the US National Institutes of Health(NIH), with additional support fromRoche.